ArticleDrugs in context2025
Evaluating the efficacy of curcumin plus serratiopeptidase formulation in inflammatory acne: a quasi-experimental study.
Article in Drugs in context, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acne vulgaris is one of the most common dermatological illnesses affecting people worldwide. In Pakistan, approximately 9.4% of the population and between 5% and 16% of young adults are affected by acne vulgaris. Conventional therapies (topical benzoyl peroxide, retinoids, antibiotics and oral isotretinoin) are effective but limited by antibiotic resistance and side effects. Curcumin (a natural anti-inflammatory/antimicrobial from turmeric) and serratiopeptidase (a proteolytic enzyme with anti-inflammatory, anti-oedematous and antibiofilm properties) each show promise in acne treatment. This article evaluates the efficacy of a combined oral curcumin plus serratiopeptidase formulation as an adjunct to inflammatory acne therapy. Methods: Fifty individuals with mild-to-moderate symptoms of inflammatory acne participated in this quasi-experimental study. They were allocated to standard therapy alone (topical regimen: benzoyl peroxide 5% and adapalene 0.1% gel; oral doxycycline 100 mg once daily) or standard therapy plus a daily curcumin (500 mg) + serratiopeptidase (10 mg) supplement (adjunctive therapy). Acne severity was assessed using a visual analogue scale (VAS) and lesion improvement scale at baseline, 1 week and 2 weeks of treatment. Data were analysed with parametric tests after normalization (log transformation), with significance set at Results: Baseline characteristics were similar between groups (mean age: 23 years; 66% female). Both groups showed significant improvement in mean VAS (from 7.5 at baseline to 3.1 at 2 weeks; Conclusion: Curcumin plus serratiopeptidase, as an adjunct to standard therapy significantly, accelerated the resolution of inflammatory acne lesions within 2 weeks, with excellent tolerability. This novel combination targets inflammatory pathways and could reduce reliance on prolonged antibiotics. Larger, longer-term studies are recommended to confirm these findings and evaluate effects on relapse and scarring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.